Eating disorder

Summary

Eating disorder (MONDO:0005451) is a disease (an umbrella term covering 6 Mondo subtypes) with 35 cohort genes (39 GWAS associations across 13 studies) and 404 clinical trials. Top therapeutic interventions include naltrexone, fluoxetine, and acipimox.

At a glance

• Umbrella term: 6 Mondo subtypes
• Cohort genes: 35
• GWAS associations: 39
• Clinical trials: 404

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	eating disorder
Mondo ID	MONDO:0005451
EFO	EFO:0005203
DOID	DOID:8670
NCIT	C89332
SNOMED CT	72366004
UMLS	C0013473
MedGen	4434
Is cancer (heuristic)	no

Also known as: eating disorder · feeding and eating disorder

Data availability: 39 GWAS associations (13 studies).

Disease family

An umbrella term covering 6 Mondo subtypes.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › eating disorder

Related subtypes (13): sexual disorder, dissociative disorder, impulse control disorder, personality disorder, cognitive disorder, factitious disorder, substance-related disorder, somatoform disorder, mental disorder, enuresis, Alice in Wonderland syndrome, catatonia, body integrity dysphoria

Subtypes (6): rumination disorder, pica disease, anorexia nervosa, bulimia nervosa, binge eating disorder, avoidant/restrictive food intake disorder

Genetics & variants

GWAS landscape

39 GWAS associations across 13 studies. Top hits map to 23 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs553488395	3e-12	LAMB1	A	4.64
rs575501818	5e-12	COTL1P1 - TBC1D27P	T	2.39
rs1185525986	7e-12	RNU6-1018P - NEFHP2	G	3.5
rs150212866	1e-11	LINC02434 - RPL7AP27	T	1.91
rs149524272	2e-11	RNA5SP228 - NPY	C	2.45
rs4854912	9e-08	SOX2-OT	T	1.91
rs138206701	1e-07	RASGRF2	A	0.33
rs13086738	2e-07	SOX2-OT	G	1.84
rs10858583	2e-07	RPL23AP68 - CYCSP30	C	1.84
rs12149074	4e-07	LINC01228 - DYNLRB2-AS1	G	1.89
rs4148087	4e-07	ABCG1	A	2
rs74566133	7e-07	MTCO1P49 - ZFAT	C	0.25
rs12475512	7e-07	B3GNT7 - ZBTB8OSP2	G	0.11
rs7322916	8e-07	ATP8A2	G	0.09
rs13077017	1e-06	FLNB	C	0.07
rs1805576	1e-06	FXR1	G	1.79
rs10175070	2e-06	CCL20	A	0.12
rs3120667	2e-06	CCDST	A	0.12
rs2115200	2e-06	SAYSD1 - KCNK5	T	0.1
rs1516459	3e-06	ROBO2	C	0.27
rs7912575	3e-06	NRG3	G	4.52
rs10998035	4e-06	LINC02640 - KRT19P4	C	0.15
rs11087123	4e-06	MACROD2	A	0.12
rs10906233	4e-06	CAMK1D	C	0.29
rs10965890	4e-06	LINC03142 - SUMO2P2	C	2.27
rs514024	5e-06	SH2D3C	A	0.06
rs2221433	5e-06	EMP2	G	0.09
rs9845942	5e-06	CRBN - SUMF1	T	1.68
rs142816172	6e-06	CSMD1	C	0.27
rs145433814	6e-06	RNA5SP94 - MIR4432HG	G	0.24

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90481817	Verma A	2024	1,754	448,642	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90473285	UK Biobank Whole-Genome Sequencing Consortium	2025	917	457,523	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90726744	Kim HI	2026	808	43,218	Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity.
GCST001959	Wade TD	2013	600	1,921	Genetic variants associated with disordered eating.
GCST001960	Wade TD	2013	543	1,116	Genetic variants associated with disordered eating.
GCST90480760	Verma A	2024	389	121,221	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90481816	Verma A	2024	389	121,221	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90481815	Verma A	2024	268	59,515	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST001961	Wade TD	2013	237	2,287	Genetic variants associated with disordered eating.
GCST003132	Liu X	2015	184	2,006	A genome-wide association study of bipolar disorder with comorbid eating disorder replicates the SOX2-OT region.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	1
Tier 3: regulatory	0
Tier 4: intronic/intergenic	35

MAF distribution

Bucket	Variants
common (>=0.05)	22
low_freq (0.01-0.05)	9
rare (<0.01)	5
unknown	0

Functional consequences

Consequence	Count
intron_variant	26
intergenic_variant	8
3_prime_UTR_variant	1
synonymous_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs553488395	7	107991243	A>G	0	intron_variant	LAMB1	3e-12	Tier 4: intronic/intergenic
rs575501818	17	16886147	T>A	0.001	intergenic_variant	COTL1P1 - TBC1D27P	5e-12	Tier 4: intronic/intergenic
rs1185525986	20	41696117	G>A,C	0.001	intron_variant	RNU6-1018P - NEFHP2	7e-12	Tier 4: intronic/intergenic
rs150212866	4	188263850	T>C	0.001	intron_variant	LINC02434 - RPL7AP27	1e-11	Tier 4: intronic/intergenic
rs149524272	7	24134044	C>T	0.001	intergenic_variant	RNA5SP228 - NPY	2e-11	Tier 4: intronic/intergenic
rs4854912	3	181063312	C>A,T	0.19	intron_variant	SOX2-OT	9e-08	Tier 4: intronic/intergenic
rs138206701	5	81110747	A>G	0.02	intron_variant	RASGRF2	1e-07	Tier 4: intronic/intergenic
rs13086738	3	181080939	A>G	0.2	intron_variant	SOX2-OT	2e-07	Tier 4: intronic/intergenic
rs10858583	12	87334666	C>T	0.23	intergenic_variant	RPL23AP68 - CYCSP30	2e-07	Tier 4: intronic/intergenic
rs12149074	16	80071969	C>A,G,T	0.37	intron_variant	LINC01228 - DYNLRB2-AS1	4e-07	Tier 4: intronic/intergenic
rs4148087	21	42202157	G>A,T	0.13	intergenic_variant	ABCG1	4e-07	Tier 4: intronic/intergenic
rs74566133	8	133766099	C>T	0.031	intergenic_variant	MTCO1P49 - ZFAT	7e-07	Tier 4: intronic/intergenic
rs12475512	2	231433365	G>A	0.457	intron_variant	B3GNT7 - ZBTB8OSP2	7e-07	Tier 4: intronic/intergenic
rs7322916	13	25433839	G>A,C	0.499	intron_variant	ATP8A2	8e-07	Tier 4: intronic/intergenic
rs13077017	3	58120049	C>A,T	0.29	intron_variant	FLNB	1e-06	Tier 4: intronic/intergenic
rs1805576	3	180949777	C>G,T	0.21	intron_variant	FXR1	1e-06	Tier 4: intronic/intergenic
rs10175070	2	227805859	G>A,C,T	0.25	intergenic_variant	CCL20	2e-06	Tier 4: intronic/intergenic
rs3120667	1	152345685	A>C,G,T	0.155	intron_variant	CCDST	2e-06	Tier 4: intronic/intergenic
rs2115200	6	39149922	T>A,C,G	0.232	intergenic_variant	SAYSD1 - KCNK5	2e-06	Tier 4: intronic/intergenic
rs1516459	3	76212669	T>A,C,G	0.032	intron_variant	ROBO2	3e-06	Tier 4: intronic/intergenic
rs7912575	10	81895974	A>G	0.01	intron_variant	NRG3	3e-06	Tier 4: intronic/intergenic
rs10998035	10	68254473	C>T	0.055	intergenic_variant	LINC02640 - KRT19P4	4e-06	Tier 4: intronic/intergenic
rs11087123	20	15140098	A>C,G	0.262	intron_variant	MACROD2	4e-06	Tier 4: intronic/intergenic
rs10906233	10	12833208	C>T	0.021	3_prime_UTR_variant	CAMK1D	4e-06	Tier 2: splice/UTR
rs10965890	9	23516290	T>A,C	0.06	intron_variant	LINC03142 - SUMO2P2	4e-06	Tier 4: intronic/intergenic
rs514024	9	127741791	G>A,C	0.428	synonymous_variant	SH2D3C	5e-06	Tier 4: intronic/intergenic
rs2221433	16	10569770	T>A,C,G	0.318	intron_variant	EMP2	5e-06	Tier 4: intronic/intergenic
rs9845942	3	3523843	C>A,G,T	0.27	intron_variant	CRBN - SUMF1	5e-06	Tier 4: intronic/intergenic
rs142816172	8	3298698	C>T	0.024	intron_variant	CSMD1	6e-06	Tier 4: intronic/intergenic
rs145433814	2	59899176	G>A	0.024	intron_variant	RNA5SP94 - MIR4432HG	6e-06	Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 44 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
RYR2	Orphanet:293888	Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant
RYR2	Orphanet:293899	Inherited isolated arrhythmogenic ventricular dysplasia, biventricular variant
RYR2	Orphanet:293910	Inherited isolated arrhythmogenic cardiomyopathy, dominant-right variant
RYR2	Orphanet:3286	Catecholaminergic polymorphic ventricular tachycardia
SET	Orphanet:178469	Autosomal dominant non-syndromic intellectual disability
SET	Orphanet:99861	Precursor T-cell acute lymphoblastic leukemia
ATP8A2	Orphanet:1766	Dysequilibrium syndrome
ATOH7	Orphanet:289499	Congenital cataract microcornea with corneal opacity
ATOH7	Orphanet:91495	Persistent hyperplastic primary vitreous
NALCN	Orphanet:1146	Distal arthrogryposis type 1
NALCN	Orphanet:1147	Sheldon-Hall syndrome
NALCN	Orphanet:2053	Freeman-Sheldon syndrome
NALCN	Orphanet:562528	Congenital limbs-face contractures-hypotonia-developmental delay syndrome
NALCN	Orphanet:700336	Hypotonia-speech impairment-severe cognitive delay syndrome due to NALCN deficiency
DYNC2I2	Orphanet:474	Jeune syndrome
DYNC2I2	Orphanet:93271	Short rib-polydactyly syndrome, Verma-Naumoff type
DNASE1L3	Orphanet:300345	Autosomal systemic lupus erythematosus
DNASE1L3	Orphanet:36412	Hypocomplementemic urticarial vasculitis
FLG2	Orphanet:263548	Peeling skin syndrome type A
EMP2	Orphanet:656	Hereditary steroid-resistant nephrotic syndrome
FGFR1	Orphanet:168953	Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement
FGFR1	Orphanet:2117	Hartsfield syndrome
FGFR1	Orphanet:220386	Semilobar holoprosencephaly
FGFR1	Orphanet:2396	Encephalocraniocutaneous lipomatosis
FGFR1	Orphanet:251576	Gliosarcoma
FGFR1	Orphanet:251579	Giant cell glioblastoma
FGFR1	Orphanet:251615	Pilomyxoid astrocytoma
FGFR1	Orphanet:2645	Osteoglosphonic dysplasia
FGFR1	Orphanet:280200	Microform holoprosencephaly
FGFR1	Orphanet:314950	Primary hypereosinophilic syndrome
FGFR1	Orphanet:3157	Septo-optic dysplasia spectrum
FGFR1	Orphanet:3366	Non-syndromic metopic craniosynostosis
FGFR1	Orphanet:432	Normosmic congenital hypogonadotropic hypogonadism
FGFR1	Orphanet:478	Kallmann syndrome
FGFR1	Orphanet:93258	Pfeiffer syndrome type 1
FGFR1	Orphanet:93924	Lobar holoprosencephaly
FGFR1	Orphanet:99798	Oligodontia
FLNB	Orphanet:1190	Atelosteogenesis type I
FLNB	Orphanet:1263	Boomerang dysplasia
FLNB	Orphanet:3275	Spondylocarpotarsal synostosis
FLNB	Orphanet:503	Larsen syndrome
FLNB	Orphanet:56305	Atelosteogenesis type III
PDE6D	Orphanet:2754	Orofaciodigital syndrome type 6
PDE6D	Orphanet:475	Isolated Joubert syndrome

Cohort genes → proteins

35 cohort genes, 34 distinct canonical proteins.

Evidence partition

Subset	Genes
gwas_only	35

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
RYR2	HGNC:10484	ENSG00000198626	Q92736	Ryanodine receptor 2	gwas
CCL20	HGNC:10619	ENSG00000115009	P78556	C-C motif chemokine 20	gwas
SET	HGNC:10760	ENSG00000119335	Q01105	Protein SET	gwas
CRNN	HGNC:1230	ENSG00000143536	Q9UBG3	Cornulin	gwas
ATP8A2	HGNC:13533	ENSG00000132932	Q9NTI2	Phospholipid-transporting ATPase IB	gwas
ATOH7	HGNC:13907	ENSG00000179774	Q8N100	Transcription factor ATOH7	gwas
CSMD1	HGNC:14026	ENSG00000183117	Q96PZ7	CUB and sushi domain-containing protein 1	gwas
MACROD2	HGNC:16126	ENSG00000172264	A1Z1Q3	ADP-ribose glycohydrolase MACROD2	gwas
CADM3	HGNC:17601	ENSG00000162706	Q8N126	Cell adhesion molecule 3	gwas
PKN3	HGNC:17999	ENSG00000160447	Q6P5Z2	Serine/threonine-protein kinase N3	gwas
NALCN	HGNC:19082	ENSG00000102452	Q8IZF0	Sodium leak channel NALCN	gwas
ZDHHC12	HGNC:19159	ENSG00000160446	Q96GR4	Palmitoyltransferase ZDHHC12	gwas
CAMK1D	HGNC:19341	ENSG00000183049	Q8IU85	Calcium/calmodulin-dependent protein kinase type 1D	gwas
SOX2-OT	HGNC:20209	ENSG00000242808		SOX2 overlapping transcript	gwas
SAYSD1	HGNC:21025	ENSG00000112167	Q9NPB0	SAYSvFN domain-containing protein 1	gwas
C4orf17	HGNC:25274	ENSG00000138813	Q53FE4	Uncharacterized protein C4orf17	gwas
ADH7	HGNC:256	ENSG00000196344	P40394	All-trans-retinol dehydrogenase [NAD(+)] ADH7	gwas
TEKT5	HGNC:26554	ENSG00000153060	Q96M29	Tektin-5	gwas
GADL1	HGNC:27949	ENSG00000144644	Q6ZQY3	Acidic amino acid decarboxylase GADL1	gwas
DYNC2I2	HGNC:28296	ENSG00000119333	Q96EX3	Cytoplasmic dynein 2 intermediate chain 2	gwas
DNASE1L3	HGNC:2959	ENSG00000163687	Q13609	Deoxyribonuclease gamma	gwas
SPHKAP	HGNC:30619	ENSG00000153820	Q2M3C7	A-kinase anchor protein SPHKAP	gwas
ZER1	HGNC:30960	ENSG00000160445	Q7Z7L7	Protein zer-1 homolog	gwas
FLG2	HGNC:33276	ENSG00000143520	Q5D862	Filaggrin-2	gwas
EMP2	HGNC:3334	ENSG00000213853	P54851	Epithelial membrane protein 2	gwas
FGFR1	HGNC:3688	ENSG00000077782	P11362	Fibroblast growth factor receptor 1	gwas
FLNB	HGNC:3755	ENSG00000136068	O75369	Filamin-B	gwas
FXR1	HGNC:4023	ENSG00000114416	P51114	RNA-binding protein FXR1	gwas
KCNK5	HGNC:6280	ENSG00000164626	O95279	Potassium channel subfamily K member 5	gwas
ABCG1	HGNC:73	ENSG00000160179	P45844	ATP-binding cassette sub-family G member 1	gwas
NUCLEOLIN	HGNC:7667	ENSG00000115053	P19338	Nucleolin	gwas
NRG3	HGNC:7999	ENSG00000185737	P56975	Pro-neuregulin-3, membrane-bound isoform	gwas
PDE6D	HGNC:8788	ENSG00000156973	O43924	Retinal rod rhodopsin-sensitive cGMP 3’,5’-cyclic phosphodiesterase subunit delta	gwas
PTMA	HGNC:9623	ENSG00000187514	P06454	Prothymosin alpha	gwas
RASGRF2	HGNC:9876	ENSG00000113319	O14827	Ras-specific guanine nucleotide-releasing factor 2	gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
RYR2	Ryanodine receptor 2	Cytosolic calcium-activated calcium channel that mediates the release of Ca(2+) from the sarcoplasmic reticulum into the cytosol and thereby plays a key role in triggering cardiac muscle contraction.
CCL20	C-C motif chemokine 20	Acts as a ligand for C-C chemokine receptor CCR6.
SET	Protein SET	Multitasking protein, involved in apoptosis, transcription, nucleosome assembly and histone chaperoning.
CRNN	Cornulin	Promotes cell proliferation, G1/S cell cycle progression and induces expression of the cell cycle regulator CCND1.
ATP8A2	Phospholipid-transporting ATPase IB	Catalytic component of a P4-ATPase flippase complex which catalyzes the hydrolysis of ATP coupled to the transport of aminophospholipids from the outer to the inner leaflet of various membranes and ensures the maintenance of asymmetric dis…
ATOH7	Transcription factor ATOH7	Transcription factor that binds to DNA at the consensus sequence 5’-CAG[GC]TG-3'.
CSMD1	CUB and sushi domain-containing protein 1	Potential suppressor of squamous cell carcinomas.
MACROD2	ADP-ribose glycohydrolase MACROD2	Removes ADP-ribose from aspartate and glutamate residues in proteins bearing a single ADP-ribose moiety.
CADM3	Cell adhesion molecule 3	Involved in cell-cell adhesion.
PKN3	Serine/threonine-protein kinase N3	Contributes to invasiveness in malignant prostate cancer.
NALCN	Sodium leak channel NALCN	Voltage-gated ion channel responsible for the resting Na(+) permeability that controls neuronal excitability.
ZDHHC12	Palmitoyltransferase ZDHHC12	Palmitoyltransferase that catalyzes the addition of palmitate onto various protein substrates.
CAMK1D	Calcium/calmodulin-dependent protein kinase type 1D	Calcium/calmodulin-dependent protein kinase that operates in the calcium-triggered CaMKK-CaMK1 signaling cascade and, upon calcium influx, activates CREB-dependent gene transcription, regulates calcium-mediated granulocyte function and res…
SAYSD1	SAYSvFN domain-containing protein 1	Ufmylation ‘reader’ component of a translocation-associated quality control pathway, a mechanism that takes place when a ribosome has stalled during translation, and which is required to degrade clogged substrates.
ADH7	All-trans-retinol dehydrogenase [NAD(+)] ADH7	Catalyzes the NAD-dependent oxidation of all-trans-retinol, alcohol, and omega-hydroxy fatty acids and their derivatives.
TEKT5	Tektin-5	Sperm-specific microtubule inner protein (MIP) part of the dynein-decorated doublet microtubules (DMTs) in flagellar axoneme.
GADL1	Acidic amino acid decarboxylase GADL1	May catalyze the decarboxylation of L-aspartate, 3-sulfino-L-alanine (cysteine sulfinic acid), and L-cysteate to beta-alanine, hypotaurine and taurine, respectively.
DYNC2I2	Cytoplasmic dynein 2 intermediate chain 2	Acts as one of several non-catalytic accessory components of the cytoplasmic dynein 2 complex (dynein-2 complex), a motor protein complex that drives the movement of cargos along microtubules within cilia and flagella in concert with the i…
DNASE1L3	Deoxyribonuclease gamma	Has DNA hydrolytic activity.
SPHKAP	A-kinase anchor protein SPHKAP	Anchoring protein that binds preferentially to the type I regulatory subunit of c-AMP-dependent protein kinase (PKA type I) and targets it to distinct subcellular compartments.
ZER1	Protein zer-1 homolog	Serves as substrate adapter subunit in the E3 ubiquitin ligase complex ZYG11B-CUL2-Elongin BC.
FLG2	Filaggrin-2	Essential for normal cell-cell adhesion in the cornified cell layers.
EMP2	Epithelial membrane protein 2	Functions as a key regulator of cell membrane composition by regulating protein surface expression.
FGFR1	Fibroblast growth factor receptor 1	Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of embryonic development, cell proliferation, differentiation and migration.
FLNB	Filamin-B	Connects cell membrane constituents to the actin cytoskeleton.
FXR1	RNA-binding protein FXR1	mRNA-binding protein that acts as a regulator of mRNAs translation and/or stability, and which is required for various processes, such as neurogenesis, muscle development and spermatogenesis.
KCNK5	Potassium channel subfamily K member 5	K(+) channel that conducts voltage-dependent outward rectifying currents upon membrane depolarization.
ABCG1	ATP-binding cassette sub-family G member 1	Catalyzes the efflux of phospholipids such as sphingomyelin, cholesterol and its oxygenated derivatives like 7beta-hydroxycholesterol and this transport is coupled to hydrolysis of ATP.
NUCLEOLIN	Nucleolin	Nucleolin is the major nucleolar protein of growing eukaryotic cells.
NRG3	Pro-neuregulin-3, membrane-bound isoform	Direct ligand for the ERBB4 tyrosine kinase receptor.
PDE6D	Retinal rod rhodopsin-sensitive cGMP 3’,5’-cyclic phosphodiesterase subunit delta	Promotes the release of prenylated target proteins from cellular membranes.
PTMA	Prothymosin alpha	Prothymosin alpha may mediate immune function by conferring resistance to certain opportunistic infections.
RASGRF2	Ras-specific guanine nucleotide-releasing factor 2	Functions as a calcium-regulated nucleotide exchange factor activating both Ras and RAC1 through the exchange of bound GDP for GTP.

Protein-family classification

Druggable: 13 · Difficult: 4 · Unknown: 18 · Druggable fraction: 0.37

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Ion channel	3	9.6×	0.038
Complement	2	15.3×	0.038
Kinase	3	2.4×	0.437
Phosphatase	1	2.4×	0.607
Transporter	1	2.2×	0.607
Antibody/Immunoglobulin	2	1.7×	0.607
Scaffold/PPI	2	1.0×	0.870
Other/Unknown	18	0.9×	0.946
Transcription factor	2	0.5×	0.953
Enzyme (other)	1	0.3×	0.953

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
RYR2	Ion channel	yes		RIH_dom, B30.2/SPRY, EF_hand_dom
CCL20	Other/Unknown	no		Chemokine_CC_CS, Chemokine_IL8-like_dom, Chemokine_CC_DCCL
SET	Other/Unknown	no		NAP, NAP-like_sf
CRNN	Other/Unknown	no		EF_hand_dom, EF-hand-dom_pair, S100_Ca-bd_sub
ATP8A2	Transcription factor	no	7.6.2.1	P_typ_ATPase, P-type_ATPase_IV, ATPase_P-typ_transduc_dom_A_sf
ATOH7	Transcription factor	no		bHLH_dom, ATOH7_bHLH, HLH_DNA-bd_sf
CSMD1	Complement	yes		Sushi_SCR_CCP_dom, CUB_dom, Sperma_CUB_dom_sf
MACROD2	Enzyme (other)	yes	3.1.1.106	Macro_dom, Macro_dom-like
CADM3	Antibody/Immunoglobulin	yes		Neurexin-like, Ig_sub2, Ig_sub
PKN3	Kinase	yes		Prot_kinase_dom, AGC-kinase_C, Ser/Thr_kinase_AS
NALCN	Ion channel	yes		Ion_trans_dom, Volt_channel_dom_sf, NALCN
ZDHHC12	Other/Unknown	no		Palmitoyltrfase_DHHC, PFA4/ZDH16/20/ERF2-like
CAMK1D	Kinase	yes	2.7.11.17	Prot_kinase_dom, Ser/Thr_kinase_AS, Kinase-like_dom_sf
SOX2-OT	Other/Unknown	no
SAYSD1	Other/Unknown	no		SAYSvFN_dom, SAYSD1
C4orf17	Other/Unknown	no		TBATA-like
ADH7	Other/Unknown	no		ADH_Zn_CS, GroES-like_sf, ADH-like_C
TEKT5	Other/Unknown	no		Tektins, Tektin-like
GADL1	Other/Unknown	no		PyrdxlP-dep_de-COase, PyrdxlP-dep_Trfase_major, PyrdxlP-dep_Trfase
DYNC2I2	Scaffold/PPI	no		WD40_rpt, WD40/YVTN_repeat-like_dom_sf, WD40_repeat_dom_sf
DNASE1L3	Phosphatase	yes		Endo/exonuclease/phosphatase, DNase_I, Deoxyribonuclease-1_AS
SPHKAP	Other/Unknown	no		SPHK1-interactor_AKAP_110, AKAP_110_C
ZER1	Other/Unknown	no		Armadillo, ARM-like, ARM-type_fold
FLG2	Other/Unknown	no		S100/CaBP7/8-like_CS, EF_hand_dom, Filaggrin
EMP2	Other/Unknown	no		EMP-2, PMP22/EMP/MP20/Claudin, PMP22_EMP_MP20
FGFR1	Kinase	yes	2.7.10.1	Prot_kinase_dom, Ser-Thr/Tyr_kinase_cat_dom, Ig_sub2
FLNB	Antibody/Immunoglobulin	yes		Filamin/ABP280_rpt, Actinin_actin-bd_CS, CH_dom
FXR1	Complement	yes		KH_dom, KH_dom_type_1, Agenet-like_dom
KCNK5	Ion channel	yes		2pore_dom_K_chnl_TASK, 2pore_dom_K_chnl, K_chnl_dom
ABCG1	Transporter	yes		ABC_transporter-like_ATP-bd, AAA+_ATPase, Pigment_permease/Abcg
NUCLEOLIN	Other/Unknown	no		RRM_dom, RRM_euk-type, Nucleotide-bd_a/b_plait_sf
NRG3	Other/Unknown	no		EGF, Neuregulin
PDE6D	Other/Unknown	no		PDED_dom, Ig_E-set, Rhodop-sen_GMP-Pdiesterase_dsu
PTMA	Other/Unknown	no		Pro/parathymosin
RASGRF2	Scaffold/PPI	no		DH_dom, Ras-like_Gua-exchang_fac_N, PH_domain

Expression context

Cohort genes with no expression data: 0.

33 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	35
unknown	0

Top tissues across cohort

Tissue	Cohort genes
middle temporal gyrus	6
Brodmann (1909) area 23	4
left ventricle myocardium	3
calcaneal tendon	3
lower esophagus mucosa	3
buccal mucosa cell	3
endothelial cell	3
mucosa of transverse colon	3
left testis	3
right testis	3
myocardium	2
ganglionic eminence	2
Brodmann (1909) area 9	2
male germ line stem cell (sensu Vertebrata) in testis	2
prefrontal cortex	2
apex of heart	2
ventricular zone	2
corpus callosum	2
esophagus mucosa	2
sperm	2

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
RYR2	210	broad	marker	heart right ventricle, left ventricle myocardium, myocardium
CCL20	202	broad	marker	epithelium of nasopharynx, cartilage tissue, gall bladder
SET	295	ubiquitous	marker	ganglionic eminence, endometrium epithelium, calcaneal tendon
CRNN	157	tissue_specific	marker	lower esophagus mucosa, tongue squamous epithelium, pharyngeal mucosa
ATP8A2	180	broad	marker	middle temporal gyrus, Brodmann (1909) area 23, orbitofrontal cortex
ATOH7	104	tissue_specific	marker	male germ line stem cell (sensu Vertebrata) in testis, prefrontal cortex, Brodmann (1909) area 9
CSMD1	179	broad	marker	Brodmann (1909) area 23, middle temporal gyrus, primary visual cortex
MACROD2	214	ubiquitous	marker	endothelial cell, buccal mucosa cell, epithelial cell of pancreas
CADM3	218	broad	marker	cerebellar hemisphere, right hemisphere of cerebellum, cerebellar cortex
PKN3	175	ubiquitous	marker	apex of heart, ventricular zone, right lung
NALCN	201	ubiquitous	marker	middle temporal gyrus, Brodmann (1909) area 23, corpus callosum
ZDHHC12	177	ubiquitous	marker	mucosa of transverse colon, lower esophagus mucosa, esophagus mucosa
CAMK1D	260	ubiquitous	marker	middle temporal gyrus, parietal lobe, postcentral gyrus
SOX2-OT	186	broad	marker	corpus callosum, subthalamic nucleus, inferior vagus X ganglion
SAYSD1	256	ubiquitous	marker	left testis, right testis, sperm
C4orf17	28	tissue_specific	marker	left ventricle myocardium, kidney epithelium, nasal cavity epithelium
ADH7	149	tissue_specific	marker	lower esophagus mucosa, esophagus mucosa, olfactory segment of nasal mucosa
TEKT5	151	tissue_specific	yes	left testis, right testis, male germ line stem cell (sensu Vertebrata) in testis
GADL1	79	tissue_specific	marker	buccal mucosa cell, germinal epithelium of ovary, hindlimb stylopod muscle
DYNC2I2	238	ubiquitous	marker	right uterine tube, pancreatic ductal cell, apex of heart
DNASE1L3	228	broad	marker	periodontal ligament, spleen, gingival epithelium
SPHKAP	127	tissue_specific	marker	left ventricle myocardium, cardiac muscle of right atrium, myocardium
ZER1	253	ubiquitous	marker	right frontal lobe, prefrontal cortex, Brodmann (1909) area 9
FLG2	122	tissue_specific	yes	upper leg skin, skin of hip, penis
EMP2	273	ubiquitous	marker	upper leg skin, upper arm skin, lower lobe of lung
FGFR1	292	ubiquitous	marker	buccal mucosa cell, stromal cell of endometrium, calcaneal tendon
FLNB	290	ubiquitous	marker	mucosa of transverse colon, tibial nerve, transverse colon
FXR1	299	ubiquitous	marker	sperm, hindlimb stylopod muscle, gastrocnemius
KCNK5	213	broad	marker	pancreatic ductal cell, mucosa of transverse colon, ileal mucosa
ABCG1	270	ubiquitous	marker	right adrenal gland, left adrenal gland, right adrenal gland cortex

Protein interactions among cohort

Intra-cohort edges: 2.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
NUCLEOLIN	5,960
FGFR1	5,693
FXR1	4,128
CCL20	2,937
FLNB	2,927
SET	2,822
RYR2	2,653
FLG2	2,574
ABCG1	2,178
CAMK1D	2,071

Intra-cohort edges

A	B	Sources
ADH7	C4orf17	string_interaction
PTMA	SET	intact

Structural data

PDB: 19 · AlphaFold-only: 15 · No structure: 1

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
FGFR1	P11362	83
PDE6D	O43924	40
RYR2	Q92736	26
FLNB	O75369	23
CAMK1D	Q8IU85	7
CCL20	P78556	6
ZER1	Q7Z7L7	6
NALCN	Q8IZF0	5
ABCG1	P45844	5
MACROD2	A1Z1Q3	4
DYNC2I2	Q96EX3	4
NUCLEOLIN	P19338	4
SET	Q01105	3
ADH7	P40394	3
FXR1	P51114	3
PTMA	P06454	2
CSMD1	Q96PZ7	1
CADM3	Q8N126	1
DNASE1L3	Q13609	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
EMP2	P54851	94.89
GADL1	Q6ZQY3	94.77
ZDHHC12	Q96GR4	88.17
TEKT5	Q96M29	85.96
ATP8A2	Q9NTI2	81.12
PKN3	Q6P5Z2	75.11
RASGRF2	O14827	73.97
ATOH7	Q8N100	72.79
KCNK5	O95279	69.94
SAYSD1	Q9NPB0	66.34
C4orf17	Q53FE4	56.75
NRG3	P56975	50.59
CRNN	Q9UBG3	49.45
SPHKAP	Q2M3C7	47.68
FLG2	Q5D862	33.09

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 101. Enrichment computed across 35 evidence-associated genes (20 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 20 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Signaling by FGFR1 amplification mutants	1	285.5×	0.091	FGFR1
ARL13B-mediated ciliary trafficking of INPP5E	1	190.3×	0.091	PDE6D
FGFR1c and Klotho ligand binding and activation	1	142.8×	0.091	FGFR1
Signaling by plasma membrane FGFR1 fusions	1	142.8×	0.091	FGFR1
Nectin/Necl trans heterodimerization	1	71.4×	0.091	CADM3
Epithelial-Mesenchymal Transition (EMT) during gastrulation	1	71.4×	0.091	FGFR1
Assembly and Release of Dengue Virus Virions	1	71.4×	0.091	NUCLEOLIN
FGFR1b ligand binding and activation	1	63.4×	0.091	FGFR1
HuR (ELAVL1) binds and stabilizes mRNA	1	63.4×	0.091	SET
HDL remodeling	1	57.1×	0.091	ABCG1
PI3K events in ERBB4 signaling	1	51.9×	0.091	NRG3
Aspartate and asparagine metabolism	1	51.9×	0.091	GADL1
Degradation of cysteine and homocysteine	1	47.6×	0.091	GADL1
Signaling by activated point mutants of FGFR1	1	47.6×	0.091	FGFR1
Ethanol oxidation	1	47.6×	0.091	ADH7
ERBB2 Activates PTK6 Signaling	1	40.8×	0.091	NRG3
FGFR1c ligand binding and activation	1	38.1×	0.091	FGFR1
Regulation of mRNA stability by proteins that bind AU-rich elements	1	38.1×	0.091	SET
SHC1 events in ERBB4 signaling	1	35.7×	0.091	NRG3
Fatty acids	1	35.7×	0.091	ADH7
ERBB2 Regulates Cell Motility	1	35.7×	0.091	NRG3
PI3K events in ERBB2 signaling	1	33.6×	0.091	NRG3
Phospholipase C-mediated cascade: FGFR1	1	33.6×	0.091	FGFR1
GRB2 events in ERBB2 signaling	1	31.7×	0.091	NRG3
ABC transporters in lipid homeostasis	1	30.1×	0.091	ABCG1
Phase 4 - resting membrane potential	1	30.1×	0.091	KCNK5
Ras activation upon Ca2+ influx through NMDA receptor	1	28.6×	0.091	RASGRF2
Downstream signaling of activated FGFR1	1	27.2×	0.091	FGFR1
Signal transduction by L1	1	25.9×	0.091	FGFR1
PI-3K cascade:FGFR1	1	25.9×	0.091	FGFR1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 32 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
involuntary skeletal muscle contraction	1	526.6×	0.048	ATP8A2
chemorepulsion involved in interneuron migration from the subpallium to the cortex	1	526.6×	0.048	NRG3
regulation of granulocyte chemotaxis	1	526.6×	0.048	CAMK1D
establishment of protein localization to endoplasmic reticulum	1	526.6×	0.048	RYR2
positive regulation of retinal ganglion cell axon guidance	1	526.6×	0.048	ATOH7
programmed cell death involved in cell development	1	263.3×	0.048	DNASE1L3
plasma membrane raft assembly	1	263.3×	0.048	EMP2
vitamin D3 metabolic process	1	263.3×	0.048	FGFR1
regulation of neutrophil mediated cytotoxicity	1	263.3×	0.048	DNASE1L3
Purkinje myocyte to ventricular cardiac muscle cell signaling	1	263.3×	0.048	RYR2
aminophospholipid translocation	1	263.3×	0.048	ATP8A2
positive regulation of mitotic cell cycle DNA replication	1	263.3×	0.048	FGFR1
positive regulation of parathyroid hormone secretion	1	263.3×	0.048	FGFR1
regulation of extrinsic apoptotic signaling pathway in absence of ligand	1	263.3×	0.048	FGFR1
regulation of phosphate transport	1	175.5×	0.048	FGFR1
glycoprotein transport	1	175.5×	0.048	ABCG1
fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development	1	175.5×	0.048	FGFR1
oviduct epithelium development	1	175.5×	0.048	CSMD1
purine nucleoside metabolic process	1	175.5×	0.048	MACROD2
regulation of lateral mesodermal cell fate specification	1	175.5×	0.048	FGFR1
mammary placode formation	1	175.5×	0.048	NRG3
actin-mediated cell contraction	1	175.5×	0.048	EMP2
cellular response to high density lipoprotein particle stimulus	1	175.5×	0.048	ABCG1
thymocyte migration	1	175.5×	0.048	CCL20
type B pancreatic cell apoptotic process	1	175.5×	0.048	RYR2
regulation of AV node cell action potential	1	175.5×	0.048	RYR2
regulation of atrial cardiac muscle cell action potential	1	175.5×	0.048	RYR2
regulation of translation at presynapse, modulating synaptic transmission	1	175.5×	0.048	FXR1
peptidyl-glutamate ADP-deribosylation	1	175.5×	0.048	MACROD2
negative regulation of mRNA catabolic process	1	175.5×	0.048	FXR1

Therapeutics

Drugs indicated for this disease

0 approved, 8 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Dasotraline	Phase 3 (in late-stage trials)
Lamotrigine	Phase 3 (in late-stage trials)
Liraglutide	Phase 3 (in late-stage trials)
Lisdexamfetamine	Phase 3 (in late-stage trials)
Olanzapine	Phase 3 (in late-stage trials)
Pramipexole	Phase 3 (in late-stage trials)
Solriamfetol	Phase 3 (in late-stage trials)
Zonisamide	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Acamprosate, Acipimox, Centanafadine, Erythromycin, Methylphenidate, Midomafetamine, Naloxone, Oxytocin, Samidorphan, Vortioxetine.

Drug target analysis

Approved (phase 4): 3 · Phase ≥3: 4 · Phased (≥1): 6 · Undrugged: 29

Druggability breadth: 16 of 35 evidence-associated genes (46%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
CAMK1D	FEDRATINIB
FGFR1	PONATINIB
PDE6D	VARDENAFIL

Top cohort targets by molecule count

Symbol	Molecules	Max phase
FGFR1	93	4
CAMK1D	25	4
PDE6D	8	4
PKN3	3	3
RYR2	1	2
SET	1	2
CCL20	0	0
CRNN	0	0
ATP8A2	0	0
ATOH7	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
FEDRATINIB	4	CAMK1D, FGFR1
RUXOLITINIB	4	CAMK1D
NERATINIB	4	CAMK1D
ENTRECTINIB	4	CAMK1D, FGFR1
TOFACITINIB CITRATE	4	CAMK1D
TOFACITINIB	4	CAMK1D
BOSUTINIB	4	CAMK1D
UPADACITINIB	4	CAMK1D, FGFR1
NINTEDANIB	4	CAMK1D, FGFR1
SUNITINIB	4	CAMK1D, FGFR1
MIDOSTAURIN	4	CAMK1D, FGFR1
PONATINIB	4	FGFR1
PEMIGATINIB	4	FGFR1
TIVOZANIB	4	FGFR1
LENVATINIB	4	FGFR1
AXITINIB	4	FGFR1
SORAFENIB	4	FGFR1, PDE6D
NICLOSAMIDE	4	FGFR1
INFIGRATINIB PHOSPHATE	4	FGFR1
INFIGRATINIB	4	FGFR1
REGORAFENIB	4	FGFR1
CABOZANTINIB	4	FGFR1
CAPIVASERTIB	4	FGFR1
VANDETANIB	4	FGFR1
NINTEDANIB ESYLATE	4	FGFR1
BRIGATINIB	4	FGFR1
ERDAFITINIB	4	FGFR1
FUTIBATINIB	4	FGFR1
PAZOPANIB	4	FGFR1
DASATINIB	4	FGFR1

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 4.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
FGFR1	1,465	Binding:1428, Functional:24, ADMET:13
CAMK1D	276	Binding:274, Functional:2
PDE6D	147	Binding:145, ADMET:2
PKN3	28	Binding:28
RYR2	15	Binding:15
ADH7	14	Binding:14
ZER1	12	Binding:12
SET	8	Binding:8
NUCLEOLIN	8	Binding:8
FLG2	6	Binding:6
FXR1	6	Binding:6
DNASE1L3	5	Binding:5
MACROD2	4	Binding:2, Toxicity:2
KCNK5	4	Binding:4
FLNB	2	Binding:2
PTMA	1	Binding:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
ATP8A2	7.6.2.1	P-type phospholipid transporter
MACROD2	3.1.1.106	O-acetyl-ADP-ribose deacetylase
CAMK1D	2.7.11.17	Ca2+/calmodulin-dependent protein kinase
FGFR1	2.7.10.1	receptor protein-tyrosine kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
CAMK1D	276
FGFR1	1,465
PDE6D	147

Pharmacogenomics

Cohort genes with a PharmGKB record: 35; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
FEDRATINIB	4	CAMK1D, FGFR1
RUXOLITINIB	4	CAMK1D
NERATINIB	4	CAMK1D
ENTRECTINIB	4	CAMK1D, FGFR1
TOFACITINIB CITRATE	4	CAMK1D
TOFACITINIB	4	CAMK1D
BOSUTINIB	4	CAMK1D
UPADACITINIB	4	CAMK1D, FGFR1
NINTEDANIB	4	CAMK1D, FGFR1
SUNITINIB	4	CAMK1D, FGFR1
MIDOSTAURIN	4	CAMK1D, FGFR1
PONATINIB	4	FGFR1
PEMIGATINIB	4	FGFR1
TIVOZANIB	4	FGFR1
LENVATINIB	4	FGFR1
AXITINIB	4	FGFR1
SORAFENIB	4	FGFR1, PDE6D
NICLOSAMIDE	4	FGFR1
INFIGRATINIB PHOSPHATE	4	FGFR1
INFIGRATINIB	4	FGFR1
REGORAFENIB	4	FGFR1
CABOZANTINIB	4	FGFR1
CAPIVASERTIB	4	FGFR1
VANDETANIB	4	FGFR1
NINTEDANIB ESYLATE	4	FGFR1
BRIGATINIB	4	FGFR1
ERDAFITINIB	4	FGFR1
FUTIBATINIB	4	FGFR1
PAZOPANIB	4	FGFR1
DASATINIB	4	FGFR1

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	3	CAMK1D, FGFR1, PDE6D
B	Phased (≥1) drug, not yet approved	3	RYR2, SET, PKN3
C	Druggable family + PDB, no drug	8	CSMD1, MACROD2, CADM3, NALCN, DNASE1L3, FLNB, FXR1, ABCG1
D	Druggable family + AlphaFold only, no drug	1	KCNK5
E	Difficult family or no structure, no drug	20	CCL20, CRNN, ATP8A2, ATOH7, ZDHHC12, SOX2-OT, SAYSD1, C4orf17, ADH7, TEKT5 (+10 more)

Undrugged target profiles

29 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
CCL20	0	—
CRNN	0	—
ATP8A2	0	—
ATOH7	0	—
CSMD1	0	—
MACROD2	4	—
CADM3	0	—
NALCN	0	—
ZDHHC12	0	—
SOX2-OT	0	—
SAYSD1	0	—
C4orf17	0	—
ADH7	14	—
TEKT5	0	—
GADL1	0	—
DYNC2I2	0	—
DNASE1L3	5	—
SPHKAP	0	—
ZER1	12	—
FLG2	6	—
EMP2	0	—
FLNB	2	—
FXR1	6	—
KCNK5	4	—
ABCG1	0	—
NUCLEOLIN	8	—
NRG3	0	—
PTMA	1	—
RASGRF2	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 404.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	369
PHASE2	10
PHASE1	9
PHASE4	6
PHASE3	5
EARLY_PHASE1	3
PHASE2/PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00000448	PHASE4	COMPLETED	Naltrexone Treatment for Alcoholic Women
NCT00060762	PHASE4	COMPLETED	Effectiveness of Binge Eating Disorder Treatments
NCT00288574	PHASE4	COMPLETED	Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa
NCT00685334	PHASE4	COMPLETED	Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa
NCT01493674	PHASE4	COMPLETED	Folic Acid Supplementation in Eating Disorder
NCT02020408	PHASE4	COMPLETED	Monoamine Contributions to Neurocircuitry in Eating Disorders
NCT00481975	PHASE3	COMPLETED	Efficacy and Safety of Rimonabant on Weight Loss and Frequency of Binge Episodes in Obese Patients
NCT01184443	PHASE3	TERMINATED	Evaluation of the Efficacy and Safety of Olanzapine for Anorexia Nervosa in Children and Adolescents
NCT03292146	PHASE3	COMPLETED	Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study
NCT03911674	PHASE3	COMPLETED	Effects of Oral Stimulation in Preterm Infants
NCT04779216	PHASE3	COMPLETED	Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa
NCT05073679	PHASE2/PHASE3	TERMINATED	Oral Naltrexone In Pediatric Eating Disorders
NCT03338387	PHASE2	ENROLLING_BY_INVITATION	Co-Feedback Action of Growth Hormone, PP and PYY on Ghrelin in Bulimia
NCT03740204	PHASE2	ACTIVE_NOT_RECRUITING	The Role of Estrogen in the Neurobiology of Eating Disorders
NCT07218302	PHASE2	NOT_YET_RECRUITING	Eating Disorder Chatbot Optimization
NCT00183586	PHASE2	COMPLETED	Comparing the Effectiveness of Three Types of Therapy for the Treatment of Anorexia Nervosa in Adolescents
NCT00283595	PHASE2	COMPLETED	Effect of Growth Hormone on Bone Metabolism in Anorexia Nervosa
NCT00304187	PHASE2	COMPLETED	Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa
NCT00494858	PHASE2	COMPLETED	Focused Versus Enhanced Cognitive Behavioral Therapy for Treating Women With Bulimia Nervosa
NCT00627341	PHASE1/PHASE2	COMPLETED	A Relapse Prevention Program for Reducing Relapse and Fear of Food in People With Anorexia Nervosa
NCT00692185	PHASE2	COMPLETED	Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa
NCT01121211	PHASE2	COMPLETED	Hormonal Factors in the Treatment of Anorexia Nervosa
NCT04278755	PHASE2	TERMINATED	Binge Eating & Birth Control
NCT06565637	PHASE1	RECRUITING	Targeting Minority Stressors to Improve Eating Disorder Symptoms in Sexual Minority Individuals With Eating Disorders
NCT00125112	PHASE1	COMPLETED	Internet Weight Control for Bingeing Adolescents
NCT00149786	PHASE1	COMPLETED	Effectiveness of Family-Based Versus Individual Psychotherapy in Treating Adolescents With Anorexia Nervosa
NCT00400933	PHASE1	TERMINATED	Evaluation of a Six-session Psycho-education Group Program
NCT00870753	PHASE1	UNKNOWN	Yoga in Treatment of Eating Disorders
NCT02284685	PHASE1	COMPLETED	A Novel Intervention Promoting Eating Disorder Treatment Among College Students
NCT03490786	PHASE1	COMPLETED	A Dose Escalating Study to Assess the Safety and Tolerability of GT-001
NCT04636840	PHASE1	COMPLETED	Leveraging Social Media to Identify and Connect Teens With Eating Disorders to a Mobile Guided Self-Help Mobile Intervention
NCT05865288	PHASE1	UNKNOWN	The Moderating Role of Baseline Oxytocin on Its Psychotherapy-facilitating Effects Among Patients With Eating Disorders
NCT05509257	EARLY_PHASE1	RECRUITING	Naltrexone Neuroimaging in Teens With Eating Disorders
NCT04686864	EARLY_PHASE1	COMPLETED	A Virtual Parent-led Support Group for Parents of Children and Youth With Eating Disorders: A Mixed Methods Feasibility Study Examining Acceptability, Cost and Parent Outcomes
NCT04935931	EARLY_PHASE1	COMPLETED	Naltrexone Neuroimaging
NCT01075672	Not specified	ACTIVE_NOT_RECRUITING	Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals
NCT02601495	Not specified	ACTIVE_NOT_RECRUITING	Latent Structure of Multi-level Assessments and Predictors of Outcomes for Women in Recovery
NCT03393039	Not specified	ACTIVE_NOT_RECRUITING	Effects of Negative Affect in Individuals With Binge Eating Episodes
NCT03808467	Not specified	ACTIVE_NOT_RECRUITING	Cognitive Training for Patients With Eating Disorders
NCT03968705	Not specified	ACTIVE_NOT_RECRUITING	Longstanding Eating Disorders and Personality Disorders

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
NALTREXONE	4	6
FLUOXETINE	4	3
ACIPIMOX	4	1
AMPHETAMINE	4	1
ARIPIPRAZOLE	4	1
BACLOFEN	4	1
ERYTHROMYCIN	4	1
FOLIC ACID	4	1
METYROSINE	4	1
OLANZAPINE	4	1
ORLISTAT	4	1
RIMONABANT	4	1
TESTOSTERONE	4	1
GLP-1	2	1
PEPTIDE YY HUMAN (3-36)	2	1
GLUCAGON-LIKE PEPTIDE 1	1	1
CHEMBL4746472	0	1
CHEMBL2354678	0	1
CHEMBL365190	0	1
CHEMBL458622	0	1